Treatment of BC by BCR-ABL TKI
| Drug . | Patients . | CR, % . | Survival . | |
|---|---|---|---|---|
| MBC/LBC . | 12 mo, % . | Median, mo . | ||
| Imatinib | ||||
| 300-600 mg28 | 58 (20 LBC) | 12 | NA | NA |
| 400-600 mg49 | 229 (MBC only) | 16 | 30 | 6.9 |
| 300-1000 mg50 | 75 (10 LBC) | 16 | 22 | 6.5 |
| 600 mg51 | 30 | 13 | 36 | 10 |
| 600 mg52 | 92 (20 LBC) | 17 | 29 | 7 |
| Dasatinib | ||||
| 50-100 mg bid54 | 33 (10 LBC) | 52/90 | ∼ 22* | ∼ 6 |
| 70-100 mg bid55 | 157 (48 LBC) | 35/56† | 49/30 | 11.8 (5.3) |
| 70 bid vs 140 mg qd56 | 210 (61 LBC) | 25-28/40-50 | 34-39/39-46 | 8 (10) |
| Nilotinib | ||||
| Up to 1200 mg58 | 33 (9 LBC) | 18 | NA | NA |
| 400-600 mg bid59 | 136 (31 LBC) | 40 | 42 | 10 |
| Drug . | Patients . | CR, % . | Survival . | |
|---|---|---|---|---|
| MBC/LBC . | 12 mo, % . | Median, mo . | ||
| Imatinib | ||||
| 300-600 mg28 | 58 (20 LBC) | 12 | NA | NA |
| 400-600 mg49 | 229 (MBC only) | 16 | 30 | 6.9 |
| 300-1000 mg50 | 75 (10 LBC) | 16 | 22 | 6.5 |
| 600 mg51 | 30 | 13 | 36 | 10 |
| 600 mg52 | 92 (20 LBC) | 17 | 29 | 7 |
| Dasatinib | ||||
| 50-100 mg bid54 | 33 (10 LBC) | 52/90 | ∼ 22* | ∼ 6 |
| 70-100 mg bid55 | 157 (48 LBC) | 35/56† | 49/30 | 11.8 (5.3) |
| 70 bid vs 140 mg qd56 | 210 (61 LBC) | 25-28/40-50 | 34-39/39-46 | 8 (10) |
| Nilotinib | ||||
| Up to 1200 mg58 | 33 (9 LBC) | 18 | NA | NA |
| 400-600 mg bid59 | 136 (31 LBC) | 40 | 42 | 10 |
CR indicates cytogenetic response (includes complete, partial, minimal, and minor response when available); LBC, lymphoid blast crisis; NA, not available; MBC, myeloid blast crisis; bid, twice a day; and qd, daily.
At 18 months.
Only complete and major cytogenetic response listed. Updated from Hehlmann and Saussele.5